finanzen.net
22.04.2019 13:07
Bewerten
(0)

Cell Viability Assays and Consumables: Global Markets

DRUCKEN

NEW YORK, April 22, 2019 /PRNewswire/ -- Report Scope:
The scope of this report is broad and covers various types of products available in the cell viability assays market and potential application sectors in various industries.The cell viability assays market is broken down by product into instruments and consumables.

Read the full report: https://www.reportlinker.com/p05770105/?utm_source=PRN

Revenue forecasts from 2018 to 2023 are given for each product, application, cell type and end user, with estimated valued derived from the revenues of manufacturers. Revenue generated from the installation and maintenance of instruments has been excluded from the report.

The report also includes a discussion of the major players in each regional cell viability assays market. Further, it explains the major drivers and regional dynamics of the global market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major players in the global cell viability assays market.

Report Includes:
- 95 data tables and 66 additional tables
- An overview of the global cell viability assays market
- Analyses of global market trends, with data from 2017, 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Information on various type of products available in the cell viability assays market and potential applications across various industries
- Examination of the main product applications and markets in an effort to help companies and investors prioritize product opportunities and strategic movements
- Evaluation of key industry and market trends, and quantification of the main market segments, allowing the reader to better understand the industry's structure and changes occurring within it
- Coverage of innovations and development in stem cell research, toxicity testing and tissue engineering
- Insight into regulatory framework and investment analysis in the healthcare sector
- Detailed profiles of the major players of the industry, including Bio-Rad Laboratories Inc., Danaher Corp., GE Healthcare, Merck KGaA and R&D Systems Inc.

Summary
Cell viability assays refer to a homogeneous method to determine the number of viable cells within a culture.Cell viability measurements are used to evaluate the effectiveness of a drug candidate, rejection of implanted organs or evaluation of the life or death of cancerous cells.

Cell viability assays are used in clinical and diagnostic applications, drug discovery and development, stem cell research, basic research and other applications such as toxicity testing and tissue engineering. Cell viability assays have proven to be extremely beneficial in drug discovery applications and the global cell viability assays market is projected to see rapid growth during the forecast period (2018-2023) owing to increasing emphasis on stem cell research and increasing demand for cell-based assays in research and development.

A surge in the number of potential biomarkers candidates for cell-based assays, growing incidence of infectious and chronic diseases and increasing focus on developing cell-based therapeutics are some of the major factors that are expected to promote the growth of global cell viability assays market.In addition, factors such as increasing healthcare expenditures and the global aging population are also providing traction for the global cell viability assays market growth during the forecast period.

The growing prevalence of infectious and chronic diseases is considered to be the major driver behind the growth of the cell viability assays market. Cell viability measurements are used to evaluate the
effectiveness of a drug candidate, rejection of implanted organs or the life or death of cancerous cells.

According to the World Health Organization (WHO), the number of patients suffering from chronic diseases such as respiratory disease, cancer and cardiovascular disease totaled about 130 million people in 2005 and is expected to reach REDACTED by 2030.In addition, increasing emphasis on stem cell research is also poised to generate strong growth opportunities for cell viability assays.

Governments globally are investing huge amounts on stem cell research. According to the U.S. Department of Health and Human Services, REDACTED billion was spent on stem cell research in 2016; this increased to REDACTED in 2017. In April 2017, Bayer AG and Versant Ventures (U.S.) announced plans to invest REDACTED to launch a stem cell research company in Canada and create a global hub for regenerative-medicinetherapies.

The global cell viability assays market is projected to rise at a compound annual growth rate (CAGR) of REDACTED during the forecast period of 2018 through 2023.Market value is expected to rise from REDACTED in 2018 to REDACTED by 2023.

Consumables held REDACTED of the market in 2017 in terms of revenue. By 2023, total revenue from consumables is expected to see a CAGR of REDACTED.

Read the full report: https://www.reportlinker.com/p05770105/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/cell-viability-assays-and-consumables-global-markets-300835499.html

SOURCE Reportlinker

Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX schließt klar im Plus -- Morgan Stanley setzt Tesla unter Druck -- Ceconomy: Umbaukosten belasten -- Daimler will wohl massiv bei Verwaltung sparen -- EVOTEC, LEONI, Siemens im Fokus

Pfund gewinnt stark nach Spekulationen über zweites Referendum. thyssenkrupp-Aufsichtsrat genehmigt Neuausrichtung einstimmig. Restaurantkette von Starkoch Jamie Oliver ist insolvent. adidas-Aktie geht nach kurzer Pause wieder auf Rekordjagd. OECD senkt globale Wachstumsprognose.

Die 5 beliebtesten Top-Rankings

Diese Aktien hat Warren Buffett im Depot
Die Änderungen unter den Top-Positionen
Die erfolgreichsten Kinofilme der letzten 25 Jahre
Welche Titel knackten die Milliardenmarke an den Kinokassen?
In diesen Berufen bekommt man das höchste Gehalt
Mit welchem Beruf kommt man am ehesten an die Spitze?
Städte für Millionäre
Hier fühlen sich die Vermögenden am wohlsten
In diesen Ländern ist Netflix am billigsten
Wo zahlen Abonnenten am wenigsten?
mehr Top Rankings

Umfrage

Die rechtspopulistische FPÖ in Österreich hat für einen Skandal gesorgt. Wie glauben Sie wird sich das auf die Europawahlen auswirken?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Huawei TechnologiesHWEI11
Daimler AG710000
TeslaA1CX3T
Deutsche Bank AG514000
CommerzbankCBK100
Amazon906866
Apple Inc.865985
BayerBAY001
BASFBASF11
NEL ASAA0B733
Deutsche Telekom AG555750
Infineon AG623100
Allianz840400
BMW AG519000